Main Claim
Daraxonrasib treatment causes inhibition of the KRAS protein, which leads to tumor shrinkage in pancreatic cancer patients.
Prometheus Claims Atlas
Daraxonrasib treatment causes inhibition of the KRAS protein, which leads to tumor shrinkage in pancreatic cancer patients.
Model focus: Daraxonrasib treatment causes inhibition of the KRAS protein, which leads to tumor shrinkage in pancreatic cancer patients.
The atlas below treats this claim as a live state of knowledge: current support, provenance, missing evidence, inconsistencies, and options for growing the model with new sources.
State Of Knowledge
What this topos world currently says
This readout treats the focus claim as a live knowledge object: what it says, where it came from, how to grow it, and what still looks weak or inconsistent.
Provenance
The focus claim is supported inside one source document; Prometheus extracted 360 candidate causal claims for audit. The strongest matching row cites 1 supporting document signal.
Grow This Model
Add papers, folders, datasets, notebooks, model outputs, or code repositories to turn this single atlas into a living topic-level state of knowledge.
Gaps And Inconsistencies
17 off-focus claim rows separated as scope drift. 0 tense overlaps and 12 regime surfaces need review. This is still a thin knowledge state: add independent studies, datasets, methods, and negative results before treating it as field-level evidence.
Grow This Topos World
Turn a claim atlas into a living research object
Each added source should either strengthen the claim, weaken it, split it into separate regimes, or expose a missing bridge. Over time, neighboring claim worlds can become objects inside a larger topos world model.
More Documents
Collect additional papers and reports that directly support, qualify, or contradict: Daraxonrasib treatment causes inhibition of the KRAS protein, which leads to tumor shrinkage in pancreatic cancer patients..
Data And Tables
Attach structured datasets, measurement tables, cohorts, endpoints, and negative results so local evidence views can split by regime.
Code And Models
Add notebooks, simulations, executable models, or analysis repositories that can ground counterfactuals and mechanistic checks.
Neighbor Worlds
Attach related topos worlds as objects: each smaller model keeps its own provenance, gaps, and inconsistencies while contributing to a larger state of knowledge.
Targeted Collection Strategy
Start where the current topos has the highest expected information gain per unit of search and extraction effort. A full Democritus run is reserved for mixed or regime-splitting evidence.
| Evidence need | Targeted search | Gain | Effort | Recommended run |
|---|---|---|---|---|
| Direct support | Daraxonrasib treatment causes inhibition of the KRAS protein, which leads to tumor shrinkage in pancreatic cancer patients. | Medium | Low | Discovery-only search before any full Democritus run |
| Contradictory evidence | Daraxonrasib treatment causes inhibition of the KRAS protein, which leads to tumor shrinkage in pancreatic cancer patients. contradiction negative result systematic review | High | Medium | Lite run on likely contradicting papers |
| Method or population split | Daraxonrasib treatment causes inhibition of the KRAS protein, which leads to tumor shrinkage in pancreatic cancer patients. cohort method endpoint measurement | High | Medium | Focused triples with method/population anchors |
Knowledge Questions
Ask what this model currently supports
Answers are grounded in the focus spine and nearby evidence views. Supporting claim surfaces remain available below for audit and drill-down.
Question Choices
Source records1
Extracted claims360
Evidence regions19
Regime checks12
Disagreements0overlaps needing attention
Model disagreement0.0216average mismatch
Focus Causal Spine
Claims shown here match the model focus closely enough to count as the current state-of-knowledge spine. Nearby but off-topic claims are kept out of this table.
| Claim | Docs | Variants | Regimes |
|---|---|---|---|
| Daraxonrasib treatment causes inhibition of the KRAS protein, which leads to tumor shrinkage in pancreatic cancer patients. | 1 | 9 | breakthrough in pancreatic cancer treatment, daraxonrasib clinical trial outcomes, daraxonrasib drug development, daraxonrasib ex... |
| The permanently active KRAS protein increases cancer progression by continuously driving tumor growth in pancreatic cancer. | 1 | 6 | breakthrough in cancer drug development, breakthrough in pancreatic cancer treatment, challenges in targeting kras protein, kras... |
| Daraxonrasib binding to the KRAS protein reduces uncontrolled cell growth by inhibiting the permanently active KRAS caused by mutations. | 1 | 3 | breakthrough in cancer drug development, molecular screening for kras binding, overcoming decades of drug discovery failures |
Relation Mix
- leads_to146
- increases86
- reduces61
- influences33
- causes27
- affects7
Off-Focus Claim Drift
17 off-focus claim rows were separated from the main spine because they do not match the model focus. This is model contamination or scope drift, not part of the top-level answer.
| Separated claim | Docs | Variants | Regimes |
|---|---|---|---|
| The binding of daraxonrasib to KRAS reduces tumor growth and increases survival in pancreatic cancer patients. | 1 | 1 | innovative drug screening methods, molecular screening for kras binding |
| The absence of druggable pockets on the KRAS protein reduces the effectiveness of traditional inhibitors, influencing resistance mechanisms in cancer cells treated with daraxonras... | 1 | 1 | kras gene mutations and cancer |
| The absence of druggable pockets on the KRAS protein leads to limitations of current screening methods for KRAS inhibitors. | 1 | 1 | challenges targeting kras protein |
| The absence of binding pockets on the mutated KRAS protein reduces the effectiveness of past drug discovery approaches targeting KRAS inhibitors. | 1 | 1 | challenges targeting kras protein |
| The absence of binding pockets on KRAS causes traditional drug discovery methods to be ineffective in designing KRAS inhibitors. | 1 | 1 | challenges targeting kras protein |
| The absence of binding pockets on KRAS causes traditional drug discovery methods to be ineffective against targeting the protein. | 1 | 1 | challenges targeting kras protein |
| Mutations in the KRAS gene cause the KRAS protein to remain permanently active, which leads to uncontrolled cell growth. | 1 | 1 | breakthrough in cancer drug development, kras gene mutations and cancer, kras protein as cancer growth driver, overcoming decades... |
| Mutations in the KRAS gene cause the KRAS protein to remain permanently active, which leads to uncontrolled cell growth in pancreatic cancer. | 1 | 1 | daraxonrasib extends pancreatic cancer survival, kras gene mutations and cancer |
Causal Spine Drill-Down
Open a focus claim to inspect supporting documents, surface variants, local regimes, and exact evidence statements from the cSQL claim table when available.
1. Daraxonrasib treatment causes inhibition of the KRAS protein, which leads to tumor shrinkage in pancreatic cancer patients.10 claims
Supporting Documents
Regime Aliases
- breakthrough in pancreatic cancer treatment
- daraxonrasib clinical trial outcomes
- daraxonrasib drug development
- daraxonrasib extends pancreatic cancer survival
- daraxonrasib targeting kras protein
- innovative drug screening methods
- kras gene mutations and cancer
- metastatic pancreatic cancer treatment
Variant Families
- daraxonrasib treatment leads_to inhibition of the kras protein, which reduces tumor size in pancreatic cancer patientsdaraxonrasib treatment leads_to inhibition of the kras protein, which reduces cancer progression by... | daraxonrasib treatment leads_to inhibition of the kras protein, which reduces uncontrolled cell gro...8 variants
- daraxonrasib treatment causes inhibition of the kras protein, which leads to tumor shrinkage in pancreatic cancer patients1 variants
Evidence Statements
| Document | Statement | Domain |
|---|---|---|
| Document 0001 | Daraxonrasib treatment causes inhibition of the KRAS protein, which leads to tumor shrinkage in pancreatic cancer patients. | patient tumor shrinkage and survival |
| Document 0001 | Daraxonrasib treatment causes inhibition of the KRAS protein, which leads to tumor shrinkage in pancreatic cancer patients. | breakthrough in pancreatic cancer treatment |
| Document 0001 | Daraxonrasib treatment leads to inhibition of the KRAS protein, which reduces cancer progression by causing tumor shrinkage. | daraxonrasib clinical trial outcomes |
| Document 0001 | Daraxonrasib treatment leads to inhibition of the KRAS protein, which reduces tumor size in pancreatic cancer patients. | kras gene mutations and cancer |
| Document 0001 | Daraxonrasib treatment leads to inhibition of the KRAS protein, which reduces uncontrolled cell growth in metastatic pancreatic cancer. | metastatic pancreatic cancer treatment |
2. The permanently active KRAS protein increases cancer progression by continuously driving tumor growth in pancreatic cancer.8 claims
Supporting Documents
Regime Aliases
- breakthrough in cancer drug development
- breakthrough in pancreatic cancer treatment
- challenges in targeting kras protein
- kras gene mutations and cancer
- kras protein as cancer growth driver
- overcoming decades of drug discovery failures
Variant Families
- the permanently active kras protein increases cancer progression by driving continuous tumor growththe permanently active kras protein increases cancer progression by continuously driving tumor grow... | the permanently active kras protein increases cancer progression by continuously driving tumor grow...6 variants
Evidence Statements
| Document | Statement | Domain |
|---|---|---|
| Document 0001 | The permanently active KRAS protein increases cancer progression by continuously driving tumor growth in pancreatic cancer. | breakthrough in pancreatic cancer treatment |
| Document 0001 | The permanently active KRAS protein increases cancer progression by continuously driving tumor growth. | challenges in targeting kras protein |
| Document 0001 | The permanently active KRAS protein increases cancer progression by continuously driving tumor growth. | breakthrough in cancer drug development |
| Document 0001 | The permanently active KRAS protein increases cancer progression by continuously signaling cells to proliferate. | kras gene mutations and cancer |
| Document 0001 | The permanently active KRAS protein increases cancer progression by driving continuous cell proliferation. | kras gene mutations and cancer |
3. Daraxonrasib binding to the KRAS protein reduces uncontrolled cell growth by inhibiting the permanently active KRAS caused by mutations.3 claims
Supporting Documents
Regime Aliases
- breakthrough in cancer drug development
- molecular screening for kras binding
- overcoming decades of drug discovery failures
Variant Families
- daraxonrasib binding to the kras protein reduces uncontrolled cell growth by inhibiting the permanently active kras proteindaraxonrasib binding to the kras protein reduces uncontrolled cell growth by inhibiting the permane... | daraxonrasib binding to the kras protein reduces uncontrolled cell growth by inhibiting the permane...3 variants
Evidence Statements
| Document | Statement | Domain |
|---|---|---|
| Document 0001 | Daraxonrasib binding to the KRAS protein reduces uncontrolled cell growth by inhibiting the permanently active KRAS caused by mutations. | molecular screening for kras binding |
| Document 0001 | Daraxonrasib binding to the KRAS protein reduces uncontrolled cell growth by inhibiting the permanently active KRAS protein caused by KRAS mutations. | overcoming decades of drug discovery failures |
| Document 0001 | Daraxonrasib binding to the KRAS protein reduces uncontrolled cell growth by inhibiting the permanently active KRAS protein. | breakthrough in cancer drug development |
Local Context Regions
Other local contexts
otherResidual contexts that do not yet fit a named atlas lens.
360 events · 18 contexts · 100% of local views
- Breakthrough in pancreatic cancer treatment42
- Breakthrough in cancer drug development39
- Daraxonrasib targeting kras protein36
- Daraxonrasib extends pancreatic cancer survival35
- Metastatic pancreatic cancer treatment32
- Molecular screening for kras binding30
- Challenges targeting kras protein29
- Challenges in targeting kras protein24
Regime Tensions
| Subject | Object | State | Regimes | Relations |
|---|---|---|---|---|
| permanently active kras protein | cancer progression | regime_sensitive | breakthrough in cancer drug development, breakthrough in pancreatic cancer treatment, challenges in targeting kras prot... | affects, increases |
| daraxonrasib treatment | pancreatic cancer patient survival | regime_sensitive | breakthrough in pancreatic cancer treatment, daraxonrasib extends pancreatic cancer survival | affects, increases |
| daraxonrasib treatment | inhibition of the kras protein | multi_regime_glued | breakthrough in pancreatic cancer treatment, daraxonrasib clinical trial outcomes, daraxonrasib drug development, darax... | causes |
| mutations in the kras gene cause the kras protein to remain permanently active which | uncontrolled cell growth | multi_regime_glued | breakthrough in cancer drug development, kras gene mutations and cancer, kras protein as cancer growth driver, overcomi... | causes |
| daraxonrasib binding to the kras protein | uncontrolled cell growth | multi_regime_glued | breakthrough in cancer drug development, molecular screening for kras binding, overcoming decades of drug discovery fai... | reduces |
| binding of daraxonrasib to kras reduces tumor growth and | survival in pancreatic cancer people | multi_regime_glued | innovative drug screening methods, molecular screening for kras binding | increases |
| daraxonrasib binding to the kras protein | tumor growth | multi_regime_glued | daraxonrasib extends pancreatic cancer survival, kras gene mutations and cancer | reduces |
| daraxonrasib treatment | cancer progression | multi_regime_glued | daraxonrasib drug development, daraxonrasib targeting kras protein | reduces |